Europe's rare disease innovators

🏆 Honored to be recognized among Europe's rare disease innovators

The rare disease landscape is being redrawn. And ODDIFACT is part of it.

We are proud to be referenced by Stifel IRIS in "Mapping Rare Disease in 2026" — one of the most comprehensive mappings of the global orphan drug ecosystem to date.

This recognition validates what we've been building: 

Transforming AI into a factory for rare diseases solutions.

While others debate the bottleneck, we're solving it:

✅ 14 Orphan Drug Designations across US and Europe in <24 months 

✅ 10 days from selection to FDA submission 

✅ Ranked #1 globally in 2024-2026

The ecosystem is ready. We have the profitable product to scale it—

turning orphan drug development into a predictable, industrial process.

300-400M people need solutions. They can't wait another decade.

WP_Rare_Disease_01_2026.pdf

Download PDF • 19.42MB